EA201690214A1 - Способ лечения гипертрофической кардиомиопатии - Google Patents

Способ лечения гипертрофической кардиомиопатии

Info

Publication number
EA201690214A1
EA201690214A1 EA201690214A EA201690214A EA201690214A1 EA 201690214 A1 EA201690214 A1 EA 201690214A1 EA 201690214 A EA201690214 A EA 201690214A EA 201690214 A EA201690214 A EA 201690214A EA 201690214 A1 EA201690214 A1 EA 201690214A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hypertrophic cardiomyopathy
treating hypertrophic
formula
treating
cardiomyopathy
Prior art date
Application number
EA201690214A
Other languages
English (en)
Inventor
Луиз Белардинелли
Рамин Фарзанех-Фар
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201690214A1 publication Critical patent/EA201690214A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Abstract

Изобретение относится к соединению формулы I или формулы IIили его фармацевтически приемлемой соли для применения в лечении гипертрофической кардиомиопатии.
EA201690214A 2013-08-01 2014-07-28 Способ лечения гипертрофической кардиомиопатии EA201690214A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361861359P 2013-08-01 2013-08-01
PCT/US2014/048495 WO2015017351A1 (en) 2013-08-01 2014-07-28 Method of treating hypertrophic cardiomyopathy

Publications (1)

Publication Number Publication Date
EA201690214A1 true EA201690214A1 (ru) 2016-07-29

Family

ID=51352822

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690214A EA201690214A1 (ru) 2013-08-01 2014-07-28 Способ лечения гипертрофической кардиомиопатии

Country Status (13)

Country Link
US (1) US9125916B2 (ru)
EP (1) EP3027189A1 (ru)
JP (1) JP2016525575A (ru)
KR (1) KR20160035060A (ru)
CN (1) CN105473143A (ru)
AU (1) AU2014296477A1 (ru)
CA (1) CA2919669A1 (ru)
EA (1) EA201690214A1 (ru)
HK (1) HK1222571A1 (ru)
MX (1) MX2016001301A (ru)
NZ (1) NZ715554A (ru)
SG (1) SG11201600102SA (ru)
WO (1) WO2015017351A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170007617A1 (en) * 2015-07-09 2017-01-12 Gilead Sciences Drive Intravenous formulations of a late sodium current inhibitor
WO2018048977A1 (en) * 2016-09-08 2018-03-15 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxazepin compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201837023A (zh) * 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
WO2013112932A1 (en) * 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers

Also Published As

Publication number Publication date
EP3027189A1 (en) 2016-06-08
HK1222571A1 (zh) 2017-07-07
CA2919669A1 (en) 2015-02-05
US20150038487A1 (en) 2015-02-05
NZ715554A (en) 2017-01-27
MX2016001301A (es) 2016-04-07
CN105473143A (zh) 2016-04-06
JP2016525575A (ja) 2016-08-25
AU2014296477A1 (en) 2016-01-28
SG11201600102SA (en) 2016-02-26
US9125916B2 (en) 2015-09-08
KR20160035060A (ko) 2016-03-30
WO2015017351A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
EA201692480A1 (ru) Фармацевтическая композиция
UA110813C2 (uk) Лікування ліподистрофії
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
EA201690844A1 (ru) Ингибиторы gsk-3
EA201500931A1 (ru) Производные пиридин-4-ила
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
EA202091873A3 (ru) Способы лечения гипотонии
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
MX2016004967A (es) Tratamiento para cancer pancreatico.
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
EA201491581A1 (ru) Везикулярные композиции
EA201590656A1 (ru) Азаиндолины
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa